Tag: respiratory biologics market share

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Respiratory Biologics Market Size Likely To Evolve From 2025 Through 2034?

The market size for respiratory biologics has shown rapid expansion in recent years. It is anticipated to increase from $6.38 billion in 2024 to $7.41 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.1%. This historical growth can be linked to factors including the increasing prevalence of respiratory diseases, the rising adoption of personalized medicine, growing healthcare expenditure globally, increasing awareness and diagnosis rates of respiratory conditions, and an expanding geriatric population with respiratory disorders.

The respiratory biologics market is anticipated to experience rapid expansion in the coming years. Its size is projected to reach $13.51 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 16.2%. This growth during the forecast period is attributable to factors such as the increasing prevalence of asthma and COPD, wider adoption of biologic therapies, higher spending on research and development, growing demand for non-invasive drug delivery, and the broadening of reimbursement policies. Major trends expected in the forecast period include the increased use of monoclonal antibodies for respiratory diseases, advancements in biologic drug formulations and delivery methods, new regulatory approvals, strategic collaborations and acquisitions among key industry players, and the integration of artificial intelligence in drug discovery and development processes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which Drivers Are Shaping The Respiratory Biologics Industry’s Market Share?

The anticipated expansion of the respiratory biologics market going forward is directly linked to the increase in air pollution. Air pollution is characterized by the presence of detrimental substances, such as gases, particulate matter, and biological molecules, within the Earth’s atmosphere, which adversely affect both human health and the environment. This rise in atmospheric contamination is a consequence of escalating industrialization and urbanization, leading to increased emissions from factories, vehicles, and construction activities. Respiratory biologics play a crucial role in countering the health impacts of air pollution by offering targeted treatments that diminish inflammation and enhance lung function in individuals exposed to airborne pollutants. For instance, in January 2025, the Environmental Protection Agency, a US-based government agency, reported that the United States released over 66 million tons of pollutants into the atmosphere in 2023. Furthermore, in September 2022, the United Nations Environment Programme, a Kenya-based environmental authority, highlighted that air pollution contributes to 7 million early deaths annually, and 99% of the world’s population breathes dirty air. Hence, the increasing air pollution is a significant driver for the growth of the respiratory biologics market.

What Are The Primary Types Of Segments Analyzed In The Respiratory Biologics Market?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

What Key Innovation Trends Are Fueling Advancements In The Respiratory Biologics Market?

Key companies in the respiratory biologics market are concentrating on developing advanced biologic therapies, such as targeted immune therapies for chronic respiratory diseases, with the goal of providing precise treatments that diminish inflammation and improve pulmonary function. Targeted immune therapies for chronic respiratory diseases are interventions designed to modulate the body’s immune system to reduce swelling and respiratory issues in long-standing lung conditions. For example, in September 2024, Sanofi S.A., a France-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who presented with an eosinophilic phenotype. This approval marked a significant milestone, making Dupixent the first biologic medicine authorized in the US for treating this specific group of COPD patients.

Who Are The Core Companies Influencing The Respiratory Biologics Market Landscape?

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Which Region Is Projected To Lead The Respiratory Biologics Market During The Forecast Period?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Respiratory Biologics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

Browse Through More Reports Similar to the Global Respiratory Biologics Market 2025, By The Business Research Company

Respiratory Disease Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pharmaceutical Drugs And Biologics Logistics Market 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market

Anesthesia And Respiratory Devices Market 2025

https://www.thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Projected Valuation Of The Respiratory Biologics Market In The Coming Years?

The market for respiratory biologics has experienced swift growth in past years. Its size is projected to escalate from $6.38 billion in 2024 to $7.41 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.1%. The significant enlargement during the historical period can be credited to the escalating prevalence of respiratory ailments, the growing acceptance of personalized medication, the global escalation in healthcare expenditure, heightened awareness and diagnosis rates of respiratory problems, and a burgeoning aged population afflicted with respiratory conditions.

The size of the respiratory biologics market is predicted to witness a rapid escalation in the coming years, predicted to expand to “$13.51 billion in 2029” with a Compound Annual Growth Rate (CAGR) of 16.2%. This anticipated growth within the forecast period can be ascribed to the growing occurrences of asthma and COPD, enhanced acceptance of biologic therapies, increased R&D investments, rising demand for non-coda drug delivery, and the broadening of reimbursement policies. Noteworthy trends expected to dominate the forecast period include the usage of monoclonal antibodies for treating respiratory ailments, improvements in biologic drug formulas and their delivery mechanisms, obtaining regulatory consents, strategic alliances and takeovers among leading players, as well as the integration of artificial intelligence in the discovery and production of drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Respiratory Biologics Market?

The escalating levels of air pollution are expected to fuel the expansion of the respiratory biologics market in the future. The term air pollution denotes the existence of detrimental elements such as gases, microscopic matter, and biological molecules in the Earth’s atmosphere, which can adversely affect human health and the environment. The rise in industrialization and urbanization lead to an increase in air pollution, as the emission of pollutants from production units, vehicles, and building activities increases. Respiratory biologics are useful in countering the health consequences of air pollution as they offer specialized therapies that decrease inflammation and enhance lung function in people exposed to airborne contaminants. For example, the Environmental Protection Agency, a US government agency, revealed in January 2025 that over 66 million tons of pollutants were emitted into the atmosphere in the United States in 2023. Additionally, as per the United Nations Environment Programme, a Kenya-based environmental authority, in September 2022, air pollution causes 7 million premature deaths each year, and 99% of the world’s population inhales polluted air. Consequently, the escalation in air pollution is spurring the expansion of the respiratory biologics market.

What Are The Key Segment Trends Observed In The Respiratory Biologics Market?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Which Disruptive Trends Are Driving Change Across The Respiratory Biologics Market?

Leading firms in the respiratory biologics market are concentrating their efforts on crafting innovative biologic therapies such as targeted immune therapies for chronic respiratory diseases. These specialized treatments are designed to modulate the body’s defense mechanism reducing inflammation and enhancing lung function. A notable example of such advancements is Sanofi S.A., a French-based pharmaceutical firm, which publicized in September 2024 that the US Food and Drug Administration (FDA) gave the green light to Dupixent (dupilumab). This is an add-on maintenance therapy for adults grappling with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This authorization sets a pivotal precedent as Dupixent is the premier biologic medicine approved in the US specifically for this category of COPD patients.

Which Firms Are Driving Innovation Within The Respiratory Biologics Market?

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

What Regional Factors Are Accelerating Growth In The Respiratory Biologics Market?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Latest Market Insights for the Biobetters Industry?#_x000D_

The significant expansion of the respiratory biologics market in the past few years has been notable. It is projected to increase from a market worth of $6.38 billion in 2024 to $7.41 billion in 2025, with a compound annual growth rate (CAGR) of 16.1%. The historical growth of this market can be credited to factors like the escalating occurrence of respiratory conditions, an increase in the adoption of personalized medicine, a surge in global healthcare expenditure, increased awareness and diagnosis rates of respiratory diseases, as well as a rising geriatric populace suffering from respiratory issues._x000D_

_x000D_

In the coming years, the respiratory biologics market size is projected to undergo swift expansion and is expected to reach “$13.51 billion in 2029 with a compound annual growth rate (CAGR) of 16.2%. The expected growth during the predicted period can be linked to the growing cases of asthma and COPD, increasing utilization of biologic therapies, rise in R&D expenditures, growing need for non-invasive medicine delivery, and widening of reimbursement policies. Noteworthy trends during this prediction period are expected to involve application of monoclonal antibodies in treating respiratory disorders, progress in formulations and delivery techniques of biologic drugs, regulatory clearances, tactical alliances and takeovers amongst influential players, and the merging of artificial intelligence in pharmaceutical research and production._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Biobetters Industry?#_x000D_

The biobetters market is predicted to expand as a result of an increasing number of chronic kidney disease (CKD) cases. CKD is characterized as a progressive ailment that disrupts and eventually halts kidney function. Factors such as an aging population, a rise in diabetes and hypertension cases, unhealthy diet, lack of physical activity, environmental contamination, and advanced diagnostic tools are contributing to the upsurge in CKD prevalence. Biobetters offer substantial benefits in managing CKD, providing superior efficacy, lesser side effects, convenient dosage schedules, and improved stability than the original biologic medicines, ultimately leading to enhanced patient outcomes. As a case in point, data from Oxford Academic, a research platform of Oxford University Press based in the UK, indicates that CKD prevalence in the UK is predicted to increase by 4% from 8.27 million to 8.61 million individuals from 2022 to 2032. The stage distribution in 2032 is anticipated at 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Hence, the escalating cases of chronic kidney diseases are propelling the growth of the biobetters market._x000D_

_x000D_

_x000D_

The respiratory biologics market covered in this report is segmented – _x000D_

_x000D_

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome_x000D_

2) By Route Of Administration: Intravenous, Subcuteneous_x000D_

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma_x000D_

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps_x000D_

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES_x000D_

_x000D_

#How Are Key Trends Driving Expansion In The Biobetters Industry?#_x000D_

Leading firms in the respiratory biologics market are prioritizing the development of cutting-edge biologic remedies. These include targeted immune therapies for chronic respiratory illnesses that can minimize inflammation and enhance lung functionality. These therapies work by managing the body’s immune system, reducing swelling, and alleviating breathing difficulties in long-term lung diseases. A case in point is the France-based pharmaceutical giant Sanofi S.A., which, in September 2024, received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab). The drug, intended as an additional maintenance therapy for adults with poorly controlled chronic obstructive pulmonary disease (COPD) exhibiting an eosinophilic phenotype, made history as Dupixent turned out to be the first biologic drug sanctioned in the US for this particular COPD patient cohort._x000D_

_x000D_

#Who Are The Primary Players Operating Across The Global Biobetters Market?#_x000D_

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc. _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report_x000D_

_x000D_

#Which Region Offers The Most Growth Potential For The Biobetters Market Through 2029?#_x000D_

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Respiratory Biologics Market, and What Factors Will Drive It?

In recent times, there has been a substantial increase in the size of the respiratory biologics market. It is projected to rise from $6.38 billion in 2024 to $7.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.1%. Factors such as escalating cases of respiratory illnesses, a surge in the implementation of personalized healthcare practices, a rise in global healthcare spending, enhanced awareness and diagnosis of respiratory conditions, and a growing older population suffering from respiratory issues have all contributed to this historical growth.

Anticipated to experience accelerated expansion in the coming years, the size of the respiratory biologics market is projected to surge to $13.51 billion in 2029 with a CAGR of 16.2%. Factors driving this growth throughout the forecast period encompass the heightened prevalence of COPD and asthma, the rising uptake of biologic therapies, the growth in R&D expenditure, escalating need for non-invasive drug administration, and broadening of reimbursement policies. The forecast period is also expected to witness some key trends such as the adoption of monoclonal antibodies for treating respiratory diseases, progress in biologic drug formulations and delivery methods, regulatory authorizations, strategic partnerships and acquisitions amongst significant players, and the amalgamation of artificial intelligence in the discovery and development of drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Respiratory Biologics Market?

The increase in air pollution is anticipated to drive the expansion of the respiratory biologics market. Air pollution, defined as the existence of detrimental substances including gases, particulate matter, and biological molecules in the Earth’s atmosphere, can have adverse effects on both human health and the environment. The surge in urbanization and industrialization is contributing to the increase in air pollution, causing elevated levels of pollutants emitted from factories, vehicles, and construction activities. Respiratory biologics are instrumental in battling the health implications of air pollution, offering targeted treatments that lower inflammation and enhance lung function in individuals subjected to airborne pollutants. For instance, the Environmental Protection Agency, a government agency based in the United States, disclosed in January 2025 that over 66 million tons of pollutants were discharged into the atmosphere in the United States in 2023. Furthermore, according to the United Nations Environment Programme, an environmental authority based in Kenya, in September 2022, air pollution leads to 7 million premature deaths every year, with 99% of the global population breathing in polluted air. Therefore, the increase in air pollution is propelling the expansion of the respiratory biologics market.

Which Key Market Segments Comprise the Respiratory Biologics Market and Drive Its Revenue Growth?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

Which Areas Are Leading Regions in the Respiratory Biologics Market Expansion Across the Globe?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theRespiratory Biologics Market Direction?

Prominent businesses in the respiratory biologics market are honing their focus on the development of inventive biologic treatments, including targeted immune therapies, for enduring respiratory ailments, with the aim of offering specialised care that mitigates inflammation and enhances lung capabilities. These therapies are geared towards managing the body’s immune response in an attempt to lessen pulmonary swelling and address breathing issues inherent in chronic lung conditions. For example, Sanofi S.A., a pharmaceutical entity based in France, made a public announcement in September 2024 that Dupixent (dupilumab) had been approved by the US Food and Drug Administration (FDA) as a supplementary maintenance treatment for adults suffering from poorly managed chronic obstructive pulmonary disease (COPD) with an underlying eosinophilic phenotype. This development was noteworthy as Dupixent earned the distinction of being the first biologically-derived medicine to receive authorization in the US for the treatment of this specific category of COPD patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

How Is the Respiratory Biologics Market Conceptually Defined?

Respiratory biologics are a class of targeted medications derived from living organisms used to treat chronic respiratory diseases. These biologics typically target specific molecules in the immune system, such as interleukins (IL-4, IL-5, IL-13) or immunoglobulin E (IgE), to reduce inflammation and improve breathing. Respiratory biologics are often prescribed for patients with severe, uncontrolled respiratory conditions that do not respond well to standard treatments like inhaled corticosteroids and bronchodilators.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23497

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Respiratory Biologics Market Size Changed, over the years?

Recent years have seen a swift expansion in the size of the respiratory biologics market. The forecast indicates a growth from $6.38 billion in 2024 to $7.47 billion in 2025, displaying a compound annual growth rate (CAGR) of 17.0%. The burgeoning growth observed in the past can be associated with factors such as the upsurge in respiratory diseases, a rise in the acceptance of personalized medicine, increased spending on healthcare worldwide, improved awareness and diagnosis of respiratory conditions, coupled with a growing older population suffering from respiratory disorders.

How Much Will the Respiratory Biologics Market Be Worth in 2029?

It is projected that the market size for respiratory biologics will experience fast-paced growth in the coming years, escalating to $13.84 billion by 2029, with a substantive compound annual growth rate (CAGR) of 16.7%. Several factors are responsible for this growth during the forecast period, including the increasing prevalence of ailments such as asthma and COPD, augmented use of biologic therapies, increased spending on R&D endeavors, heightened demand for non-invasive methods of drug delivery, and broader reimbursement policies. Key factors expected to shape the market in this forecast period include the application of monoclonal antibodies in treating respiratory diseases, breakthroughs in the formulation and delivery of biologic drugs, regulatory approvals, strategic partnerships and acquisitions among leading players, and the incorporation of artificial intelligence in the discovery and development of new drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which is the Largest Company in the Respiratory Biologics Market?

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

What Are the Main Market Drivers in the Respiratory Biologics Industry?

The growth of the respiratory biologics market is being accelerated by the uptick in air pollution. Air pollution, which encompasses the introduction of damaging substances like gases, particulate matter, and biological molecules into the Earth’s atmosphere, poses significant threats to both human health and the environment. Factors such as growing industrialization and urbanization are escalating air pollution levels as they trigger an increase in pollutant emissions from factories, vehicles, and construction activities. To mitigate the detrimental health implications of air pollution, respiratory biologics offers targeted treatments that alleviate inflammation and enhance lung functionality in individuals exposed to airborne contaminants. For example, the Environmental Protection Agency, a US government body, reported in January 2025 that the United States had discharged over 66 million tons of pollutants into the atmosphere in 2023. Furthermore, the United Nations Environment Programme, an environmental authority based in Kenya, stated in September 2022 that due to air pollution, 7 million premature deaths occur annually, and 99% of the global population inhales unclean air. Consequently, the escalation in air pollution is catalyzing the expansion of the respiratory biologics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

How Is the Respiratory Biologics Market Segments Structured?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegment:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

What Strategic Trends Are Transforming the Respiratory Biologics Market?

Leading firms in the respiratory biologics market are prioritizing the development of novel biologic therapies, such as targeted immune therapies for chronic respiratory ailments, in order to deliver more precise treatments that alleviate inflammation and enhance lung functionality. These targeted immune therapies aim to manage the body’s immune response so as to decrease swelling and alleviate breathing issues linked to long-term lung diseases. To illustrate, Sanofi S.A., a pharmaceutical company based in France, made an announcement in September 2024 that Dupixent (dupilumab) had received approval from the US Food and Drug Administration (FDA) for use as an adjunct maintenance therapy in adults suffering from inadequately managed chronic obstructive pulmonary disease (COPD) exhibiting an eosinophilic phenotype. This authorization symbolizes a significant breakthrough, with Dupixent being the first biologic drug to get approval in the US for the treatment of this particular subset of COPD patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Which Global Regions Offer the Highest Growth in the Respiratory Biologics Market?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23497

This Report Delivers Insight On:

1. How big is the respiratory biologics market, and how is it changing globally?

2. Who are the major companies in the respiratory biologics market, and how are they performing?

3. What are the key opportunities and risks in the respiratory biologics market right now?

4. Which products or customer segments are growing the most in the respiratory biologics market?

5. What factors are helping or slowing down the growth of the respiratory biologics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Respiratory Biologics Market Size Changed, over the years?

Recent years have seen a swift expansion in the size of the respiratory biologics market. The forecast indicates a growth from $6.38 billion in 2024 to $7.47 billion in 2025, displaying a compound annual growth rate (CAGR) of 17.0%. The burgeoning growth observed in the past can be associated with factors such as the upsurge in respiratory diseases, a rise in the acceptance of personalized medicine, increased spending on healthcare worldwide, improved awareness and diagnosis of respiratory conditions, coupled with a growing older population suffering from respiratory disorders.

How Much Will the Respiratory Biologics Market Be Worth in 2029?

It is projected that the market size for respiratory biologics will experience fast-paced growth in the coming years, escalating to $13.84 billion by 2029, with a substantive compound annual growth rate (CAGR) of 16.7%. Several factors are responsible for this growth during the forecast period, including the increasing prevalence of ailments such as asthma and COPD, augmented use of biologic therapies, increased spending on R&D endeavors, heightened demand for non-invasive methods of drug delivery, and broader reimbursement policies. Key factors expected to shape the market in this forecast period include the application of monoclonal antibodies in treating respiratory diseases, breakthroughs in the formulation and delivery of biologic drugs, regulatory approvals, strategic partnerships and acquisitions among leading players, and the incorporation of artificial intelligence in the discovery and development of new drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which is the Largest Company in the Respiratory Biologics Market?

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

What Are the Main Market Drivers in the Respiratory Biologics Industry?

The growth of the respiratory biologics market is being accelerated by the uptick in air pollution. Air pollution, which encompasses the introduction of damaging substances like gases, particulate matter, and biological molecules into the Earth’s atmosphere, poses significant threats to both human health and the environment. Factors such as growing industrialization and urbanization are escalating air pollution levels as they trigger an increase in pollutant emissions from factories, vehicles, and construction activities. To mitigate the detrimental health implications of air pollution, respiratory biologics offers targeted treatments that alleviate inflammation and enhance lung functionality in individuals exposed to airborne contaminants. For example, the Environmental Protection Agency, a US government body, reported in January 2025 that the United States had discharged over 66 million tons of pollutants into the atmosphere in 2023. Furthermore, the United Nations Environment Programme, an environmental authority based in Kenya, stated in September 2022 that due to air pollution, 7 million premature deaths occur annually, and 99% of the global population inhales unclean air. Consequently, the escalation in air pollution is catalyzing the expansion of the respiratory biologics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

How Is the Respiratory Biologics Market Segments Structured?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegment:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

What Strategic Trends Are Transforming the Respiratory Biologics Market?

Leading firms in the respiratory biologics market are prioritizing the development of novel biologic therapies, such as targeted immune therapies for chronic respiratory ailments, in order to deliver more precise treatments that alleviate inflammation and enhance lung functionality. These targeted immune therapies aim to manage the body’s immune response so as to decrease swelling and alleviate breathing issues linked to long-term lung diseases. To illustrate, Sanofi S.A., a pharmaceutical company based in France, made an announcement in September 2024 that Dupixent (dupilumab) had received approval from the US Food and Drug Administration (FDA) for use as an adjunct maintenance therapy in adults suffering from inadequately managed chronic obstructive pulmonary disease (COPD) exhibiting an eosinophilic phenotype. This authorization symbolizes a significant breakthrough, with Dupixent being the first biologic drug to get approval in the US for the treatment of this particular subset of COPD patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Which Global Regions Offer the Highest Growth in the Respiratory Biologics Market?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23497

This Report Delivers Insight On:

1. How big is the respiratory biologics market, and how is it changing globally?

2. Who are the major companies in the respiratory biologics market, and how are they performing?

3. What are the key opportunities and risks in the respiratory biologics market right now?

4. Which products or customer segments are growing the most in the respiratory biologics market?

5. What factors are helping or slowing down the growth of the respiratory biologics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!

What Are the Key Projections for the CAGR of the Respiratory Biologics Market Size From 2025 to 2034?

In the past few years, an accelerated expansion has been observed in the respiratory biologics market. The market size which was $6.38 billion in 2024 is expected to climb up to $7.47 billion in 2025, witnessing a compound annual growth rate (CAGR) of 17.0%. Factors that have contributed to the growth during the historic period include the escalating frequency of respiratory illnesses, the increasing trend of personalized medicine, the global rise in healthcare spending, enhanced awareness and diagnosis rates of respiratory conditions, and the increase in elderly population suffering from respiratory disorders.

Expectations are high for significant expansion in the respiratory biologics market in the coming years. The market is projected to reach $13.84 billion by 2029, with a compound annual growth rate of 16.7%. This anticipated surge over the forecast period can be linked to factors such as the increasing incidence of asthma and COPD, more widespread use of biologic therapies, enhanced investment in research and development, growing demand for non-invasive methods of drug delivery, and extensive reimbursement policies. Key trends to look out for during this period encompass the adoption of monoclonal antibodies for treating respiratory conditions, progress in biologic drug formulations and delivery systems, regulatory approvals, strategic partnerships and acquisitions among prominent players, and the incorporation of artificial intelligence into drug discovery and development processes.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Respiratory Biologics Market?

The escalating levels of air pollution are poised to catalyze the expansion of the respiratory biologics market moving forward. Air pollution, denoting the occurrence of detrimental substances like gases, particulate matter, and biological molecules in the earth’s atmosphere, has an adverse impact on both human health and the environment. The augmentation in air pollution can be traced back to increasing industrialization and urbanization, contributing to heightened discharge of pollutants from factories, vehicles, and construction operations. Respiratory biologics provide a solution to the health detriments of air pollution by offering targeted treatments that pull back inflammation and enhance lung function in those exposed to airborne pollutants. For instance, per the Environmental Protection Agency, a government agency in the US, it was reported that in 2023, over 66 million tons of pollutants were emitted into the atmosphere in the United States. In addition, the United Nations Environment Programme, an environmental authority based in Kenya, stated in September 2022 that yearly, air pollution causes 7 million premature deaths, and 99% of the world’s population are breathing impure air. As a result, the swelling in air pollution is fueling the advancement of the respiratory biologics market.

Which Segments in the Respiratory Biologics Offer the Most Growth?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegment:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

What Are the Fastest-Growing Geographies in the Respiratory Biologics Market?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Respiratory Biologics Industry?

The focus of key players in the respiratory biologics market is shifting towards creating innovative biologic solutions such as specialized immune therapies catered to chronic respiratory illnesses. These therapies aim to regulate the body’s immune system to reduce inflammation and enhance lung functionality. In examples, Sanofi S.A., a pharmaceutical firm based in France, made a major announcement in September 2024 regarding the approval of Dupixent (dupilumab) by the US Food and Drug Administration (FDA). This treatment, used as an add-on maintenance therapy for adults suffering from poorly managed chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype, marked a prominent milestone. It was the first biologic treatment to gain U.S. approval for this specific COPD patient population.

View the full report here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

What Are the Key Elements That Define the Respiratory Biologics Market?

Respiratory biologics are a class of targeted medications derived from living organisms used to treat chronic respiratory diseases. These biologics typically target specific molecules in the immune system, such as interleukins (IL-4, IL-5, IL-13) or immunoglobulin E (IgE), to reduce inflammation and improve breathing. Respiratory biologics are often prescribed for patients with severe, uncontrolled respiratory conditions that do not respond well to standard treatments like inhaled corticosteroids and bronchodilators.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23497

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model